SRPT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Sarepta Therapeutics Inc (SRPT) does not present a strong buy opportunity for a beginner, long-term investor at this time. The technical indicators are mixed, with bearish moving averages and a high RSI suggesting overbought conditions. Additionally, hedge funds are heavily selling, and analysts' ratings are largely cautious or negative. While there are some positive developments in early-stage trials, the risks and uncertainties surrounding its core revenue stream and clinical trials outweigh the potential upside.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is at 74.005, suggesting overbought conditions. The moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading near its resistance level (R1: 17.457). This indicates limited immediate upside potential.
Positive early-stage data from Phase 1/2 trials for SRP-1001 and SRP-1003, which showed strong safety profiles and dose-dependent plasma exposure. Analysts like Wedbush and Oppenheimer have raised price targets based on these developments.
Hedge funds are selling heavily, with a 12693.27% increase in selling activity over the last quarter. Analysts like H.C. Wainwright and Deutsche Bank have expressed concerns about the risks of Sarepta's clinical trials and limited upside for its core revenue stream. The stock is also overbought based on RSI, and bearish moving averages signal caution.
No financial data available for analysis.
Analyst ratings are mixed to negative. While some firms like Wedbush and Oppenheimer have raised price targets and remain optimistic, others like H.C. Wainwright, Deutsche Bank, and Citi have reiterated Sell ratings and highlighted significant risks. The price targets range widely, from $5 to $37, reflecting uncertainty in the stock's future performance.
